Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Public Health | Research

Cancer patterns in Iran: a gender-specific spatial modelling of cancer incidence during 2014–2017

Authors: Sharareh Faramarzi, Behzad Kiani, Shahla Faramarzi, Neda Firouraghi

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Cancer is a significant public health concern and the second leading cause of death. This study aims to visualize spatial patterns of top common cancer types and identify high-risk and low-risk counties for these cancers in Iran from 2014 to 2017.

Methods

In this study, we analyzed 482,229 newly diagnosed cancer cases recorded by the Iranian National Population-Based Cancer Registry from 2014 to 2017. We employed a purely spatial scanning model and local Moran I analysis to explore spatial patterns across Iran.

Results

Approximately 53% of all cases were male. The average age of cancer diagnosis was 62.58 ± 17.42 years for males and 56.11 ± 17.33years for females. Stomach cancer was the most common cancer in men. The northern and northwestern regions of Iran were identified as high-risk areas for stomach cancer in both genders, with a relative risk (RR) ranging from 1.26 to 2.64 in males and 1.19 to 3.32 in females. These areas recognized as high-risk areas for trachea, bronchus, and lung (TBL) cancer specifically in males (RR:1.15–2.02). Central regions of Iran were identified as high-risk areas for non-melanoma skin cancers in both genders, ranking as the second most common cancer (RR:1.18–5.93 in males and 1.24–5.38 in females). Furthermore, bladder cancer in males (RR:1.32–2.77) and thyroid cancer in females (RR:1.88–3.10) showed concentration in the central part of Iran. Breast cancer, being the most common cancer among women (RR:1.23–5.54), exhibited concentration in the northern regions of the country. Also, northern regions of Iran were identified as high-risk clusters for colon cancer (RR:1.31–3.31 in males and 1.33–4.13 in females), and prostate cancer in males (RR:1.22–2.31). Brain, nervous system cancer, ranked sixth among women (RR:1.26–5.25) in central areas.

Conclusions

The study's revelations on the spatial patterns of common cancer incidence in Iran provide crucial insights into the distribution and trends of these diseases. The identification of high-risk areas equips policymakers with valuable information to tailor targeted screening programs, facilitating early diagnosis and effective disease control strategies.
Appendix
Available only for authorised users
Literature
1.
Yomralioglu T, Colak EH, Aydinoglu AC. Geo-relationship between cancer cases and the environment by GIS: a case study of Trabzon in Turkey. Int J Environ Res Public Health. 2009;6(12):3190–204.PubMedPubMedCentralCrossRef
2.
Gulland A. Global cancer prevalence is growing at “alarming pace”, says WHO. BMJ. 2014;348:g1338.PubMedCrossRef
3.
Mohammadi E, Aminorroaya A, Fattahi N, Azadnajafabad S, Rezaei N, Farzi Y, et al. Epidemiologic pattern of cancers in Iran; current knowledge and future perspective. J Diabetes Metab Disord. 2021;20(1):825–9.PubMedCrossRef
4.
Rahimi F, Heidari M. time trend analysis of stomach cancer incidence in the West of Iran. Health Dev J. 2012;1(2):100–11.
5.
Almasi Z, Rafiemanesh H, Salehiniya H. Epidemiology characteristics and trends of incidence and morphology of stomach cancer in Iran. Asian Pac J Cancer Prev. 2015;16(7):2757–61.PubMedCrossRef
6.
Mohebbi M, Mahmoodi M, Wolfe R, Nourijelyani K, Mohammad K, Zeraati H, et al. Geographical spread of gastrointestinal tract cancer incidence in the Caspian Sea region of Iran: spatial analysis of cancer registry data. BMC Cancer. 2008;8(1):137.PubMedPubMedCentralCrossRef
7.
Dolatkhah R, Somi MH, Kermani IA, Ghojazadeh M, Jafarabadi MA, Farassati F, et al. Increased colorectal cancer incidence in Iran: a systematic review and meta-analysis. BMC Public Health. 2015;15:997.PubMedPubMedCentralCrossRef
8.
Mungi C, Lai D, Du XL. Spatial analysis of industrial benzene emissions and cancer incidence rates in Texas. Int J Environ Res Public Health. 2019;16(15):2627.PubMedPubMedCentralCrossRef
9.
Armstrong BK, Kricker A, English DR. Sun exposure and skin cancer. Australas J Dermatol. 1997;38(Suppl 1):S1-6.PubMed
10.
Sadykova LR, Ntekim AI, Muyangwa-Semenova M, Rutland CS, Jeyapalan JN, Blatt N, et al. Epidemiology and risk factors of osteosarcoma. Cancer Invest. 2020;38(5):259–69.PubMedCrossRef
11.
Ambroggi M, Biasini C, Del Giovane C, Fornari F, Cavanna L. Distance as a barrier to cancer diagnosis and treatment: review of the literature. Oncologist. 2015;20(12):1378–85.PubMedPubMedCentralCrossRef
12.
Etemadi A, Abnet CC, Kamangar F, Islami F, Khademi H, Pourshams A, et al. Impact of body size and physical activity during adolescence and adult life on overall and cause-specific mortality in a large cohort study from Iran. Eur J Epidemiol. 2014;29(2):95–109.PubMedPubMedCentralCrossRef
13.
Taylor DP, Burt RW, Williams MS, Haug PJ, Cannon-Albright LA. Population-based family history-specific risks for colorectal cancer: a constellation approach. Gastroenterology. 2010;138(3):877–85.PubMedCrossRef
14.
Brenner H, Kloor M, Pox CP. Colorectal cancer. The Lancet. 2014;383(9927):1490–502.CrossRef
15.
Kim HI, Lim H, Moon A. Sex differences in cancer: epidemiology. Genet Ther Biomol Ther (Seoul). 2018;26(4):335–42.CrossRef
16.
Sadjadi A, Nouraie M, Mohagheghi MA, Mousavi-Jarrahi A, Malekezadeh R, Parkin DM. Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev. 2005;6(3):359–63.PubMed
17.
Kiani B, Raouf Rahmati A, Bergquist R, Hashtarkhani S, Firouraghi N, Bagheri N, et al. Spatio-temporal epidemiology of the tuberculosis incidence rate in Iran 2008 to 2018. BMC Public Health. 2021;21(1):1093.PubMedPubMedCentralCrossRef
18.
Firouraghi N, Mohammadi A, Hamer DH, Bergquist R, Mostafavi SM, Shamsoddini A, et al. Spatio-temporal visualisation of cutaneous leishmaniasis in an endemic, urban area in Iran. Acta Trop. 2022;225:106181.PubMedCrossRef
19.
Dadashi A, Mohammadi A, MohammadEbrahimi S, Bergquist R, Shamsoddini A, Hesami A, et al. Spatial analysis of the 10 most prevalent cancers in north-eastern Iran, 2017–2018. J Spat Sci. 2021:1–21.
20.
Babaee E, Roshandel G, Olfatifar M, Tehrani-Banihashemi A, Ashaari A, Nojomi M. Geo-epidemiological reporting and spatial clustering of the 10 most prevalent cancers in Iran. Geospat Health. 2021;16(1).
21.
Soleimani M, Saeini MR, Jalilvand A. Spatial and temporal analysis of gastric cancer incidence in northwest Iran. GeoJournal. 2023.
22.
Montazeri M, Hoseini B, Firouraghi N, Kiani F, Raouf-Mobini H, Biabangard A, et al. Spatio-temporal mapping of breast and prostate cancers in South Iran from 2014 to 2017. BMC Cancer. 2020;20(1):1170.PubMedPubMedCentralCrossRef
23.
Khoshdel A, Alimohammadi M, Sepandi M, Alimohamadi Y, Jalali P, Janani M. Spatio-temporal analysis of colorectal cancer using a geographic information system in the Iranian military community during the period 2007–2016. BMJ Mil Health. 2020;166(E):e8–12.PubMedCrossRef
24.
25.
Roshandel G, Ghanbari-Motlagh A, Partovipour E, Salavati F, Hasanpour-Heidari S, Mohammadi G, et al. Cancer incidence in Iran in 2014: results of the iranian national population-based cancer registry. Cancer Epidemiol. 2019;61:50–8.PubMedCrossRef
26.
Bray F, Parkin DM. Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer. 2009;45(5):747–55.PubMedCrossRef
27.
Fritz APC, Jack A, et al. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
28.
Kulldorff M. A spatial scan statistic. Commun Stat Theory Methods 26:1481–961997.
29.
30.
Anselin L. Local Indicators of spatial association—LISA. Geogr Anal. 1995;27(2):93–115.CrossRef
31.
32.
SaTScan - Technical Documentation Available online Accessed 15 Oct 2022.
33.
34.
35.
Sharifian A, Pourhoseingholi MA, Emadedin M, Rostami Nejad M, Ashtari S, Hajizadeh N, et al. Burden of breast cancer in Iranian women is increasing. Asian Pac J Cancer Prev. 2015;16(12):5049–52.PubMedCrossRef
36.
Roshandel G, Ferlay J, Ghanbari-Motlagh A, Partovipour E, Salavati F, Aryan K, et al. Cancer in Iran 2008 to 2025: recent incidence trends and short-term predictions of the future burden. Int J Cancer. 2021;149(3):594–605.PubMedCrossRef
37.
Abdi E, Latifi-Navid S, Yazdanbod A, Zahri S. Helicobacter pylori babA2 positivity predicts risk of gastric cancer in ardabil, a very high-risk area in Iran. Asian Pac J Cancer Prev. 2016;17(2):733–8.PubMedCrossRef
38.
Maleki I, Mohammadpour M, Zarrinpour N, Khabazi M, Mohammadpour RA. Prevalence of Helicobacter pylori infection in Sari Northern Iran; a population based study. Gastroenterol Hepatol Bed Bench. 2019;12(1):31–7.PubMedPubMedCentral
39.
Ghasemi Kebria F, Bagheri H, Semnani S, Ghaemi E. Seroprevalence of anti-Hp and anti-cagA antibodies among healthy persons in Golestan province, northeast of Iran (2010). Caspian J Intern Med. 2011;2(3):256–60.PubMedPubMedCentral
40.
Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med. 2009;12(6):576–83.PubMed
41.
Shakeri R, Malekzadeh R, Etemadi A, Nasrollahzadeh D, Abedi-Ardekani B, Khoshnia M, et al. Association of tooth loss and oral hygiene with risk of gastric adenocarcinoma. Cancer Prev Res (Phila). 2013;6(5):477–82.PubMedCrossRef
42.
Shakeri R, Malekzadeh R, Etemadi A, Nasrollahzadeh D, Aghcheli K, Sotoudeh M, et al. Opium: an emerging risk factor for gastric adenocarcinoma. Int J Cancer. 2013;133(2):455–61.PubMedCrossRef
43.
Pourfarzi F, Whelan A, Kaldor J, Malekzadeh R. The role of diet and other environmental factors in the causation of gastric cancer in Iran–a population based study. Int J Cancer. 2009;125(8):1953–60.PubMedCrossRef
44.
González CA, Jakszyn P, Pera G, Agudo A, Bingham S, Palli D, et al. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006;98(5):345–54.PubMedCrossRef
45.
Chandanos E, Lagergren J. Oestrogen and the enigmatic male predominance of gastric cancer. Eur J Cancer. 2008;44(16):2397–403.PubMedCrossRef
46.
Kiani B, Tabari P, Mohammadi A, Mostafavi SM, Moghadami M, Amini M, et al. Spatial epidemiology of skin cancer in Iran: separating sun-exposed and non-sun-exposed parts of the body. Arch Public Health. 2022;80(1):35.PubMedPubMedCentralCrossRef
47.
Razi S, Enayatrad M, Mohammadian-Hafshejani A, Salehiniya H, Fathali-loy-dizaji M, Soltani S. The epidemiology of skin cancer and its trend in Iran. Int J Prev Med. 2015;6:64.PubMedPubMedCentralCrossRef
48.
49.
Fartasch M, Diepgen TL, Schmitt J, Drexler H. The relationship between occupational sun exposure and non-melanoma skin cancer: clinical basics, epidemiology, occupational disease evaluation, and prevention. Dtsch Arztebl Int. 2012;109(43):715–20.PubMedPubMedCentral
50.
Ardestani EG, Mokhtari A. Modeling the lumpy skin disease risk probability in central Zagros Mountains of Iran. Prev Vet Med. 2020;176:104887.PubMedCrossRef
51.
Shahbazi-Gahrouei D. Possible effect of background radiation on cancer incidence in Chaharmahal and Bakhtiari province. Int J Radiat Res. 2003;1(3):171–4.
52.
Yang X, Chen H, Zhang S, Chen X, Sheng Y, Pang J. Association of cigarette smoking habits with the risk of prostate cancer: a systematic review and meta-analysis. BMC Public Health. 2023;23(1):1150.PubMedPubMedCentralCrossRef
53.
Hassanipour S, Fathalipour M, Salehiniya H. The incidence of prostate cancer in Iran: a systematic review and meta-analysis. Prostate Int. 2018;6(2):41–5.PubMedCrossRef
54.
Rafiemanesh H, Lotfi Z, Bakhtazad S, Ghoncheh M, Salehiniya H. The epidemiological and histological trend of bladder cancer in Iran. J Cancer Res Ther. 2018;14(3):532–6.PubMedCrossRef
55.
Jafari-Koshki T, Arsang-Jang S, Mahaki B. Bladder cancer in iran: geographical distribution and risk factors. Int J Cancer Manag. 2017;10(2):e5610.
56.
Zeegers MP, Kellen E, Buntinx F, van den Brandt PA. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol. 2004;21(6):392–401.PubMedCrossRef
57.
Lakkis NA, Adib SM, Hamadeh GN, El-Jarrah RT, Osman MH. Bladder Cancer in Lebanon: Incidence and comparison to Regional and Western Countries. Cancer Control. 2018;25(1):1073274818789359.PubMedPubMedCentralCrossRef
58.
Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306(7):737–45.PubMedPubMedCentralCrossRef
59.
Sohrabi M-R, Abbasi-Kangevari M. Kolahi A-A. Current Tobacco Smoking Prevalence Among Iranian Population: A Closer Look at the STEPS Surveys. Frontiers in Public Health; 2020. p. 8.
60.
Lotfi MH, Farzaneh F, Mehrparvar AH, Fallahzadeh MH, Sadeghian MR. The effect of smoking and opium on bladder cancer in Yazd Province: a case - control study. J Community Health Res. 2016;5(2):98–109.
61.
Afshari M, Janbabaei G, Bahrami MA, Moosazadeh M. Opium and bladder cancer: a systematic review and meta-analysis of the odds ratios for opium use and the risk of bladder cancer. PLoS ONE. 2017;12(6):e0178527.PubMedPubMedCentralCrossRef
62.
Pishgar E, Fanni Z, Tavakkolinia J, Mohammadi A, Kiani B, Bergquist R. Mortality rates due to respiratory tract diseases in Tehran, Iran during 2008–2018: a spatiotemporal, cross-sectional study. BMC Public Health. 2020;20(1):1414.PubMedPubMedCentralCrossRef
63.
Ghasemi S, Mahaki B, Dreassi E, Aghamohammadi S. Spatial variation in lung cancer mortality and related men-women disparities in Iran from 2011 to 2014. Cancer Manag Res. 2020;12:4615–24.PubMedPubMedCentralCrossRef
64.
Didkowska J, Wojciechowska U, Mańczuk M, Łobaszewski J. Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Transl Med. 2016;4(8):150.PubMedPubMedCentralCrossRef
65.
Sadjadi A, Nouraie M, Ghorbani A, Alimohammadian M, Malekzadeh R. Epidemiology of breast cancer in the Islamic Republic of Iran: first results from a population-based cancer registry. East Mediterr Health J. 2009;15:1426–31.PubMed
66.
White AJ, Keller JP, Zhao S, Carroll R, Kaufman JD, Sandler DP. Air pollution, clustering of particulate matter components, and breast cancer in the sister study: A U.S.-wide cohort. Environ Health Perspect. 2019;127(10):107002.PubMedPubMedCentralCrossRef
67.
Karimi H, Soffianian A, Mirghaffari N, Soltani S. Determining air pollution potential using geographic information systems and multi-criteria evaluation: a case study in Isfahan Province in Iran. Environ Proc. 2016;3(1):229–46.CrossRef
68.
Heger M, Sarraf M. Air pollution in Tehran. 2018.
69.
Comparison of Bayesian Spatial Ecological Regression Models or Investigating the Incidence of Breast Cancer in Iran, 2005–008. Asian Pac J Cancer Prev. 2015;16(14):5669–73.PubMedCrossRef
70.
Roohparvarzade N. Prevalence of risk factors for breast cancer in women (20 to 69 Years old) in Isfahan 2012–2013. Iranian J Breast Diseases. 2014;7(1):52–61.
71.
Mousavi SM, Mohaghegghi MA, Mousavi-Jerrahi A, Nahvijou A, Seddighi Z. Burden of breast cancer in Iran: a study of the Tehran population based cancer registry. Asian Pac J Cancer Prev. 2006;7(4):571–4.PubMed
72.
Akhtari-Zavare M, Ghanbari-Baghestan A, Latiff LA, Matinnia N, Hoseini M. Knowledge of breast cancer and breast self-examination practice among Iranian women in Hamedan. Iran Asian Pac J Cancer Prev. 2014;15(16):6531–4.PubMedCrossRef
73.
Djalalinia S, Saeedi Moghaddam S, Sheidaei A, Rezaei N, Naghibi Iravani SS, Modirian M, et al. Patterns of Obesity and overweight in the Iranian population: findings of STEPs 2016. Front Endocrinol (Lausanne). 2020;11:42.PubMedCrossRef
74.
Kitahara CM, Pfeiffer RM, Sosa JA, Shiels MS. Impact of overweight and obesity on US papillary thyroid cancer incidence trends (1995–2015). J Natl Cancer Inst. 2020;112(8):810–7.PubMedCrossRef
75.
Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27.PubMedCrossRef
76.
Parad MT, Fararouei M, Mirahmadizadeh AR, Afrashteh S. Thyroid cancer and its associated factors: A population-based case-control study. Int J Cancer. 2021;149(3):514–21.PubMedCrossRef
77.
Von Behren J, Reynolds P. Birth characteristics and brain cancers in young children. Int J Epidemiol. 2003;32(2):248–56.CrossRef
78.
Agnihotri SK, Kesari KK. Mechanistic Effect of Heavy Metals in Neurological Disorder and Brain Cancer. In: Kesari KK, editor. Networking of Mutagens in Environmental Toxicology. Cham: Springer International Publishing; 2019. p. 25–47.CrossRef
79.
Oloumi H, salari h, Mousavi E, Afazali D. Lead contamination in soil and vegetation of areas surrounding different mining activity zones in Kerman Province of Iran. Afr J Biotechnol. 2012;11:14146.
80.
Ravanipour M, Hadi M, Rastkari N, Hemmati Borji S, Nasseri S. Presence of heavy metals in drinking water resources of Iran: a systematic review and meta-analysis. Environ Sci Pollut Res Int. 2021;28(21):26223–51.PubMedCrossRef
81.
Soltani-Gerdefaramarzi S, Ghasemi M, Gheysouri M. Pollution, human health risk assessment and spatial distribution of toxic metals in urban soil of Yazd City. Iran Environm Geochemist Health. 2021;43(9):3469–84.CrossRef
82.
Soltani-Gerdefaramarzi S, Ghasemi M, Ghanbarian B. Geogenic and anthropogenic sources identification and ecological risk assessment of heavy metals in the urban soil of Yazd, central Iran. PLoS ONE. 2021;16(11):e0260418.PubMedPubMedCentralCrossRef
83.
Ryan P, Lee MW, North B, McMichael AJ. Risk factors for tumors of the brain and meninges: results from the adelaide adult brain tumor study. Int J Cancer. 1992;51(1):20–7.PubMedCrossRef
84.
Sohrabi MR, Abbasi-Kangevari M, Kolahi AA. Current tobacco smoking prevalence among iranian population: a closer look at the STEPS surveys. Front Public Health. 2020;8:571062.PubMedPubMedCentralCrossRef
Metadata
Title
Cancer patterns in Iran: a gender-specific spatial modelling of cancer incidence during 2014–2017
Authors
Sharareh Faramarzi
Behzad Kiani
Shahla Faramarzi
Neda Firouraghi
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11940-4

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis

Research

Metabolic subtypes and immune landscapes in esophageal squamous cell carcinoma: prognostic implications and potential for personalized therapies

Research

Increased resected lymph node stations improved survival of esophageal squamous cell carcinoma

Research

Identification of prognostic signatures in remnant gastric cancer through an interpretable risk model based on machine learning: a multicenter cohort study

Research

Gut microbiota composition and metabolic characteristics in patients with Craniopharyngioma

Research

The application of different machine learning models based on PET/CT images and EGFR in predicting brain metastasis of adenocarcinoma of the lung
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits